# V1 Empirics Check — google/gemini-3-flash-preview (Variant B)

**Model:** google/gemini-3-flash-preview
**Variant:** B
**Date:** 2026-03-30T10:53:24.895208

---

**Referee Report**

**Title:** The Registration Effect: Transparency Mandates and Selective Reporting in Clinical Trials  
**Author:** APEP Autonomous Research  

---

### 1. Idea Fidelity
The paper maintains high fidelity to the original idea manifest. It correctly identifies the core policy variation (FDAAA 801 phase-based exemption), utilizes the specified data source (ClinicalTrials.gov), and executes the primary Difference-in-Differences (DiD) strategy. It successfully incorporates the suggested heterogeneity analysis (Industry vs. Academic) and geographic splits (US vs. Non-US). One minor omission from the manifest is the "Second dose" analysis of the 2017 Final Rule; the author intentionally limits the sample to 2015 to "allow sufficient time for results posting," which is a defensible econometric choice but skips the 2017 variation mentioned in the manifest.

### 2. Summary
The paper estimates the causal effect of the FDAAA 801 transparency mandate on clinical trial reporting by comparing mandated Phase 2/3 trials to exempt Phase 1 trials. The author finds a 10 percentage point increase in results reporting attributed to the mandate, though this effect is entirely concentrated among industry-sponsored trials (22 p.p.) where regulatory enforcement is credible. The study highlights that transparency mandates in scientific markets require substantive enforcement mechanisms rather than just normative shifts to be effective.

### 3. Essential Points

1.  **Violation of Parallel Trends:** The placebo test in Column 1 of Table 5 is highly concerning. A coefficient of 0.224 ($p < 0.01$) for a "fake" treatment in the pre-period is larger than the actual treatment effect. This suggests the Phase 1 vs. Phase 2/3 comparison fails the fundamental DiD assumption. While the author discusses this in the "Mechanisms" and "Discussion" sections, the paper currently presents the 10 p.p. "pooled" estimate as a primary result. If the pre-trends are this divergent, the pooled DiD is biased, and the paper should lead with the heterogeneity analysis (Sponsor Type) as the only potentially credible source of identification.
2.  **Inference with Few Clusters:** The author clusters standard errors by "start year," resulting in only 13 clusters. Standard asymptotic theory for clustering typically requires 30-50 clusters. While the author mentions "wild cluster bootstrap" in the text, these results are not explicitly reported in the tables. Given the small number of years, the $t$-statistics in Table 2 (where $N=13$) are likely inflated. The author must provide the Wild Bootstrap $p$-values to confirm significance.
3.  **Treatment of Results Posting Lag:** FDAAA 801 requires reporting within one year of the *Primary Completion Date*, yet the model uses *Start Year* for its "Post" indicator and clustering. Trials started in 2006 might end in 2009 and thus be subject to the law, while trials started in 2008 might not be expected to report until 2012. The current specification ignores the "Completion Date" which is the actual trigger for the legal reporting requirement.

---

### 4. Suggestions

**Econometric Refinements**
*   **Alternative Control Group:** Given the failure of parallel trends with Phase 1 trials, consider a "Triple-Difference" (DDD) approach. Use Phase 2/3 vs. Phase 1 (first diff) $\times$ Post-2007 (second diff) $\times$ Industry vs. Academic (third diff). This would netting out the "phase-specific" trends that are currently contaminating the placebo test.
*   **Wait-Time Analysis:** Instead of a binary "has results posted" indicator, use a hazard model or a "days to posting" outcome. The API provides `ResultsFirstPostDate` and `PrimaryCompletionDate`. Measuring the gap between these would more accurately capture the "1-year requirement" of the law.
*   **Clustering by Therapeutic Area:** To increase the number of clusters, consider clustering at the disease/condition level (using MeSH terms or the `condition` field) rather than the start year. This would allow for much more robust inference.

**Data and Measurement**
*   **Phase 1/2 Exclusion:** The author excludes Phase 1/2 trials. I suggest using them as a "Medium Intensity" treatment group. Exploring whether they behave more like Phase 1 or Phase 2 would provide a useful "dose-response" check.
*   **The 2017 "Second Dose":** The original manifest suggested using the 2017 Final Rule (which added \$10k/day penalties). Adding this as a second step-function in the DiD would significantly strengthen the "enforcement" argument, which is currently the paper's strongest contribution.
*   **Outcome Switching:** The manifest mentioned "outcome switching rate" as an outcome. The paper focuses on the *count* of primary outcomes. Both are valuable. A reduction in the count might indicate "strategic parsimony" (as the author notes), but checking if the *identity* of the primary outcome changed after registration (using version history) would be a major contribution to the "selective reporting" literature.

**Contextual and Interpretative Improvements**
*   **ICMJE Clarification:** The author correctly identifies the 2004 ICMJE mandate as a confounder. However, the ICMJE required *registration*, not *results reporting*. The paper should more clearly distinguish between the "registration effect" (getting the trial on the site) and the "reporting effect" (putting data in the tables).
*   **Mechanism of the Industry Effect:** Why specifically does Industry respond more? It’s not just "FDA interaction." Many industry trials are for "Applicable Clinical Trials" linked to New Drug Applications (NDAs). If a result isn't posted, the FDA can withhold approval for the next drug. Academic investigators don't have this "hostage" dynamic. Adding a paragraph on the specific regulatory linkages (e.g., Form FDA 3674) would improve the "Institutional Background."
*   **Figure Recommendation:** The paper lacks a visual event-study plot. Given the pre-trend issues, a plot of reporting rates by year for Phase 1 and Phase 2/3 trials is essential for an AER: Insights format to allow the reader to judge the "parallel-ish" nature of the trends visually.
